JP2022535880A - ｃ－ＭＥＴ阻害剤を使用して癌患者を処置するための方法 - Google Patents

ｃ－ＭＥＴ阻害剤を使用して癌患者を処置するための方法 Download PDF

Info

Publication number
JP2022535880A
JP2022535880A JP2021572340A JP2021572340A JP2022535880A JP 2022535880 A JP2022535880 A JP 2022535880A JP 2021572340 A JP2021572340 A JP 2021572340A JP 2021572340 A JP2021572340 A JP 2021572340A JP 2022535880 A JP2022535880 A JP 2022535880A
Authority
JP
Japan
Prior art keywords
met
cancer
gene
alkyl
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021572340A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020244654A5 (https=
JP2022535880A5 (https=
Inventor
ヤン，ラン
シ，キァン
レドゥカ，サンジーヴ
ユ，グオリャン
マウリツィオ ベネデッティ，ファビオ
ジャン，シャオリン
マ，ビャオ
Original Assignee
アポロミクス インコーポレイテッド（ハンジョウ）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アポロミクス インコーポレイテッド（ハンジョウ） filed Critical アポロミクス インコーポレイテッド（ハンジョウ）
Publication of JP2022535880A publication Critical patent/JP2022535880A/ja
Publication of JPWO2020244654A5 publication Critical patent/JPWO2020244654A5/ja
Publication of JP2022535880A5 publication Critical patent/JP2022535880A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2021572340A 2019-06-06 2020-06-08 ｃ－ＭＥＴ阻害剤を使用して癌患者を処置するための方法 Pending JP2022535880A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2019090294 2019-06-06
CNPCT/CN2019/090294 2019-06-06
CN2019092706 2019-06-25
CNPCT/CN2019/092706 2019-06-25
CN2019109906 2019-10-08
CNPCT/CN2019/109906 2019-10-08
PCT/CN2020/094824 WO2020244654A1 (en) 2019-06-06 2020-06-08 Method for treating cancer patients using c-met inhibitor

Publications (3)

Publication Number Publication Date
JP2022535880A true JP2022535880A (ja) 2022-08-10
JPWO2020244654A5 JPWO2020244654A5 (https=) 2023-06-15
JP2022535880A5 JP2022535880A5 (https=) 2023-06-15

Family

ID=73653139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572340A Pending JP2022535880A (ja) 2019-06-06 2020-06-08 ｃ－ＭＥＴ阻害剤を使用して癌患者を処置するための方法

Country Status (6)

Country Link
US (1) US20220252603A1 (https=)
EP (1) EP3980783A4 (https=)
JP (1) JP2022535880A (https=)
CN (1) CN114599978A (https=)
CA (1) CA3142642A1 (https=)
WO (1) WO2020244654A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112592976B (zh) * 2020-12-30 2021-09-21 深圳市海普洛斯生物科技有限公司 一种检测met基因扩增的方法及装置
MX2023012434A (es) * 2021-04-21 2024-02-08 Apollomics Inc Diagnostico y tratamiento de cancer usando inhibidor de c-met.
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537966A (ja) * 2010-08-31 2013-10-07 ジェネンテック， インコーポレイテッド バイオマーカー及び治療の方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008113013A2 (en) * 2007-03-15 2008-09-18 University Of Chicago C-met mutations and uses thereof
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
CN106008339B (zh) * 2016-06-08 2018-09-07 上海准视生物科技有限公司 一种放射性c-met靶向亲和小分子化合物及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537966A (ja) * 2010-08-31 2013-10-07 ジェネンテック， インコーポレイテッド バイオマーカー及び治療の方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HU HUIMIN ET AL.: "Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor", CELL, vol. 175, JPN6024019061, 2018, pages 1665 - 1678, ISSN: 0005447424 *
HUGHES PAUL E. ET AL.: "In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Depend", MOL CANCER THER, vol. vol. 15, mo. 7, JPN6024019060, 2016, pages 1568 - 1579, ISSN: 0005447425 *
SHIH JOE. ET AL.: "Bozitinib, a highly selective inhibitor of c-Met, demonstrates robust activity in gastric, lung, hep", CANCER RES, vol. Abstract 2096, JPN6024043245, 2017, ISSN: 0005447426 *

Also Published As

Publication number Publication date
CA3142642A1 (en) 2020-12-10
WO2020244654A1 (en) 2020-12-10
EP3980783A4 (en) 2023-09-13
EP3980783A1 (en) 2022-04-13
CN114599978A (zh) 2022-06-07
US20220252603A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
JP2022535880A (ja) ｃ－ＭＥＴ阻害剤を使用して癌患者を処置するための方法
US20240218453A1 (en) Diagnostic and treatment of cancer using c-met inhibitor
US11473151B2 (en) Diagnostic and therapeutic methods for cancer
EP3198026B1 (en) Method of determining pik3ca mutational status in a sample
CN109476731A (zh) 治疗癌症的方法
HK1226108A1 (zh) 用於癌症治疗的诊断方法和组合物
TW202138566A (zh) 透過循環腫瘤dna分析之分子疾病評估之方法及系統
WO2023064784A1 (en) Cd274 rearrangements as predictors of response to immune checkpoint inhibitor therapy
JP2008533991A (ja) 肺癌におけるｃ−ｍｅｔ突然変異
JP7597450B2 (ja) 大腸癌の治療のためのアビツズマブ
CN105765078A (zh) Vegf抑制剂长期有效性预测方法
Zabriskie et al. A novel AGGF1-PDGFRb fusion in pediatric T-cell acute lymphoblastic leukemia
JP6669500B2 (ja) 薬物耐性ａｋｔ変異体を検出し治療するための方法及び組成物
WO2021063970A1 (en) PREDICTIVE BIOMARKERS FOR TREATMENT OF A CANCER PATIENT WITH TGFβ SIGNALING PATHWAY INHIBITORS
JP6858563B2 (ja) Ｂｒａｆ変異検出によるｅｇｆｒ阻害剤の効果予測
JP2025541293A (ja) Ｃ－ｍｅｔ阻害剤を用いた、ｅｇｆｒ ｔｋｉに耐性があるがんの治療
HK40130056A (zh) 使用c-met抑制剂治疗对egfr tki具有耐药性的癌症
JP2022517563A (ja) タンパク質キナーゼバイオマーカーと組み合わせた、多標的キナーゼ阻害剤を使用したがんの処置
WO2021063972A1 (en) Cthrc1 as biomarker for a tgfbeta-activated tumor microenvironment
KR20220044504A (ko) 개인 hla 패턴의 결정, 예후인자로서의 용도, 표적 유전자 및 치료제
Glückstein et al. ALK, NUT, and TRK Do Not Play Relevant Roles in Gastric Cancer—Results of an Immunohistochemical Study in a Large Series. Diagnostics 2022, 12, 429
US20120107308A1 (en) Gene expression levels of egfr, vegfr2, and ercc1 associated with clinical outcomes of chemotherapy
Cushman-Vokoun Somatic Alterations and Targeted Therapy
HK40061707A (en) Cancer treatment using multi-targeted kinase inhibitor in combination of protein kinase biomarkers
HK1241934A1 (en) Method of determining pik3ca mutational status in a sample

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241029